Kornimate/medical-research-clean huggingface dataset:
observational study on the qol of ras wild-type mcrc patients receiving anti-egfr mabs + folfox or folfiri as 1st line

Conditions: Metastatic Colorectal Cancer

Summary: this is a national, multicentric, prospective, observational trial. the decision to prescribe folfox or folfiri plus panitumumab or folfox or folfiri plus cetuximab must have been freely taken by the clinician prior to the study entry for each patient included. each physician will see his/her patients within the context of routine visits, without any special visit being organised for the purposes of the study. therefore, the doctor-patient relationship and patient follow-up are not modified. physicians are totally free to decide on their patients' therapeutic management. eortc qlq-c30 and dlqi questionnaires will be completed by the patients at baseline (day 1 of cycle 1), at the first day of every other cycle (every 2 weeks) thereafter, and at ""end of study visit" (within 28 days from the end of treatment with anti-egfr or withdrawal from study for any reason). before every cycle, adverse events will be recorded and graded according to nci ctcae v4.0. treatment's modifications in terms of cycles' delay, dose reductions or drugs' interruptions will be recorded. concomitant approaches to prevent or treat dermatological toxicities during the treatment will be registered.


Eligibility criteria:
inclusion criteria:- adult (\>= 18 years old) ras wild-type metastatic colorectal cancer patients candidate to receive folfox or folfiri plus panitumumab or folfox or folfiri plus cetuximab as upfront treatment as per clinical practice * willingness and ability to comply with the protocol * written informed consent to study procedures * exclusion criteria: - patients receiving a treatment under clinical investigation may not be included in the study * previous treatment with an anti-egfr monoclonal antibody

Keywords: metastatic colorectal cancer gene ras not mutated "wild type"
clinical performance of habitual wearers of bioclear 1-day lenses when refitted with biomedics 1-day extra for 1 week

Conditions: Myopia; Hyperopia

Summary: open label, 1-week daily disposable, dispensing study

evaluate the clinical performance of habitual wearers of filcon iv 1 sphere lenses when refitted with ocufilcon d asphere for 1 week of daily disposable wear.

Eligibility criteria:
inclusion criteria: * is between 18 and 40 years of age (inclusive) * has had a self-reported visual exam in the last two years * is an adapted avaira sphere contact lens wearer (at least 1 week in avaira sphere) * has a contact lens spherical prescription between + 2.25 to - 8.00 (inclusive) * has a spectacle cylinder up to 0.75d in each eye. * can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logmar) or better in each eye. * can achieve a distance visual acuity of 20/30 (0.18 logmar) or better in each eye with the study contact lenses. * has clear corneas and no active ocular disease * has read, understood and signed the information consent letter. * patient contact lens refraction should fit within the available parameters of the study lenses. * is willing to comply with the wear schedule (at least 5 days per week, \> 8 hours/day assuming there are no contraindications for doing so). * is willing to comply with the visit schedule exclusion criteria: * is not a habitual wearer of avaira sphere lenses * has a cl prescription outside the range of the available parameters of the study lenses. * has a spectacle cylinder ≥1.00d of cylinder in either eye. * has a history of not achieving comfortable cl wear (5 days per week; \> 8 hours/day) * has contact lens best corrected distance vision worse than 20/25 (0.10 logmar) in either eye. * presence of clinically significant (grade 2-4) anterior segment abnormalities * presence of ocular or systemic disease or need of medications which might interfere with contact lens wear. * slit lamp findings that would contraindicate contact lens wear such as: * pathological dry eye or associated findings * pterygium, pinguecula, or corneal scars within the visual axis * neovascularization \> 0.75 mm in from of the limbus * giant papillary conjunctivitis (gcp) worse than grade 1 * anterior uveitis or iritis (past or present) * seborrheic eczema, seborrheic conjunctivitis * history of corneal ulcers or fungal infections * poor personal hygiene * has a known history of corneal hypoesthesia (reduced corneal sensitivity) * has aphakia, keratoconus or a highly irregular cornea. * has presbyopia or has dependence on spectacles for near work over the contact lenses. * has undergone corneal refractive surgery. * is participating in any other type of eye related clinical or research study
comprehensive digital archive of cancer imaging-radiation oncology( chavi-ro )

Conditions: All Cancer

Summary: in this pilot project investigators propose to create annotated image data bank of patients suffering from cancer. the system will provide india's first comprehensive platform to upload annotated images with associated medical and demographic information of a patient. it will support flexible query from the users with appropriate choice from a set of attributes and design of various query filters using a gui. over the proposed period of 18 months, images and records related to radiation oncology including pretreatment images of at least 500 patients would be annotated and archived in the data bank. the imaging modalities to be covered are x-ray mammograms, spect, ct, cbct, mr, pet-ct, ultrasound, digital histopathology, etc. in this phase, this study will include data sets of five types of cancers namely, breast, head and neck, brain, cervix and lung cancer. investigator propose to demonstrate the application of this data set in cancer research. investigator will work on serial pet-ct based radiomics of breast and cervix cancer patients to extract appropriate features and correlate them with clinico-pathological variants.


Eligibility criteria:
inclusion criteria: 1. patients undergoing radiotherapy planned with volumetric imaging. - exclusion criteria: * informed consent not given

Keywords: carcinoma radiomics image processing radiology molecular biology data analytics center artificial intelligence medical physics big data radiation oncology
lenvatinib plus deb-tace and haic vs. lenvatinib plus deb-tace for large hcc with pvtt

Conditions: Hepatocellular Carcinoma Non-resectable

Summary: this study is conducted to evaluate the efficacy and safety of lenvatinib plus transarterial chemoembolization (tace) with drug-eluting beads (deb-tace) and hepatic artery infusion chemotherapy (haic) with folfox regemen (len+deb-tace+haic) versus lenvatinib plus deb-tace (len+deb-tace) for large hepatocellular carcinoma (\> 7cm) with portal vein tumor thrombosis (pvtt).

this is a multicenter, prospective and randomized study to evaluate the efficacy and safety of len+deb-tace+haic compared with len+deb-tace for unresectable large hcc (\>7cm) with pvtt. 178 patients with large hcc (\> 7cm) and pvtt will be enrolled in this study. the patients will receive either len+deb-tace+haic or len+deb-tace using an 1:1 randomization scheme. in the len+deb-tace+haic arm, the microcatheter will be reserved at the main hepatic tumor-feeding artery after deb-tace and chemotherapy drugs (oxaliplatin, fluorouracil and leucovorin; folfox-based regimen) will be intra-arterially administered though the microcatheter. deb-tace+haic treatments can be repeated based on the evaluation of follow-up laboratory and imaging examination by the multidisciplinary team. in the len+deb-tace arm, patients will be treated with deb-tace alone. tace treatment can be repeated based on the evaluation of follow-up laboratory and imaging examination by the multidisciplinary team. in both arms, lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) p.o. qd will be started within 7 days after the first deb-tace+haic/deb-tace. the primary end point of this study is time to progression (ttp). the secondary endpoints are tumor response (objective response rate and disease control rate), overall survival (os), and adverse events (aes).

Eligibility criteria:
inclusion criteria: * a confirmed diagnosis of hcc * the largest intrahepatic lesion \>7 cm * presence of pvtt on imaging * tumor recurrence after curative treatment (hepatectomy or ablation) is eligible for enrollment * eastern cooperative oncology group performance status ≤1 * child-pugh class a/b * adequate hematologic and organ function, with leukocyte count\>3.0×10\^9/l, neutrophil count\>1.5×10\^9/l, platelet count≥75×10\^9/l, hemoglobin 85 g/l, alanine transaminase and aspartate transaminase≤5×upper limit of the normal, creatinine clearance rate≤1.5×upper limit of the normal * life expectancy of at least 3 months exclusion criteria: * diffuse hcc * accompanied with vena cava tumor thrombus * central nervous system involvement * previous treatment with tace, haic, tae, radiotherapy, or systemic therapy * organ (heart and kidneys) dysfunction, unable to tolerate tace or haic treatment * history of other malignancies * uncontrollable infection * history of hiv * history of organ or cells transplantation * prothrombin time prolongation \>4 s

Keywords: hepatocellular carcinoma lenvatinib transarterial chemoembolization drug-eluting bead hepatic arterial infusion chemotherapy portal vein tumor thrombosis
evaluation of efficacy of coadministration of fov1101-00 and prednisolone acetate in patients with mild ongoing ocular allergic inflammation

Conditions: Allergic Conjunctivitis

Summary: this is a phase 2 study that will consist of 3 visits during a 3 week period conducted at up to 5 sites. the purpose of this study is to determine how effective the combination of pred mild® and fov1101-00 is compared to either pred forte® alone or to vehicle alone in the prevention of eye allergies. study subjects will be randomized to one of the following: * fov1101-00 concentration 1 and pred mild® * fov1101-00 concentration 2 and pred mild® * vehicle of fov1101-00 and pred forte® * vehicle of fov1101-00 and vehicle of fov1101-00


Eligibility criteria:
inclusion criteria: * history of ocular allergies and a positive skin test reaction to allergens within the past 24 months and a history of chronic eye irritation; exclusion criteria: * active ocular infection; clinically significant blepharitis; follicular conjunctivitis; iritis; any type of glaucoma; ocular surgery within past 3 months; pregnancy or nursing
mazor x stealth versus o-arm navigation for pedicle screw insertion

Conditions: Disorder of Spine

Summary: the investigators would like to investigate the fluoro-registered mazor x stealth in terms of pedicle screw accuracy and radiation exposure in comparison with the o-arm and navigation as the institutional gold standard.

pedicle screw insertion for spinal fusion is a surgical procedure regularly performed around the world. surgeons use free-hand, navigation or robotic techniques. the navigation began in 1995 in spine surgery. surgical navigation systems provide pedicle screw insertion by projecting screw trajectories on a three-dimensional (3d) image acquisition, preoperatively or during the surgical procedure. laine et al reported better accuracy and safety in pedicle screw insertion using the navigation system. other authors reported less irradiation with the use of computer-assisted navigation. robotic guidance was introduced in 2006 and assists the surgeon through a mechanical guidance according to a planning of screw trajectories on 3d imaging. this technique allows stable guidance for pedicle drilling and screw insertion, leading to greater screw positioning in lumbar fusion. medtronic (medtronic, minneapolis, mn, usa) introduced the mazor x stealth in europa in 2019, including the mazor robotic device with the navigation technology within the same system. the hypothesis would be a combination of the stability of the robot during screw insertion and the accuracy of the navigation with cumulative benefit from the two techniques. the goal of this study is to compare radiological and clinical results of the use of the new mazor stealth with the surgical o-arm navigation during pedicle screw insertion for posterior lumbar fusion.

Eligibility criteria:
inclusion criteria: * adult patients * who require pedicle screw insertion for vertebral posterior stabilization exclusion criteria: * children * participants incapable of judgment * participants under tutelage * vertebral fusion indication without pedicle screw implantation * refusal to participate * data missing for radiation exposure calculation * unstable vertebral fracture requiring urgent fixation * pregnancy * refusal to participate

Keywords: vertebral instability spondylolisthesis discopathy
muscle mass loss in critically ill patients.

Conditions: Muscle Loss

Summary: the purpose of the study is to describe the change in muscle mass in critically ill patients. the study will examine rectus femoris cross sectional area with ultrasound and identify risk factors of this changes.

the study will commence following the approval by the ethics research committee. all patients admitted to our icu from the 1st of march 2019 to the 31st of august 2019 will be enrolled after fulfilling the inclusion criteria and in the absence of any exclusion criteria. informed consent will be requested. ultrasound measurement of rectus femoris cross sectional area will be performed in first 24 hours after admission to icu. study data will be entered in study form. the ultrasound measurement will be repeated on day 7 of hospitalisation. changes in rectus femoris cross sectional area and potential risk factors will be analysed. the length of icu length of stay and 28-day mortality will be also monitored.

Eligibility criteria:
inclusion criteria: * age ≥18 years * mechanical ventilation expected for at least 48 hours exclusion criteria: * clinical frailty score above 7 prior admission * neuromuscular disease in previous medical history * amputated lower extremities * trauma of lower extremities involving tights * age under 18 years * inability to perform ultrasound examination * death or discharge prior completion of protocol * full verticalization prior completion of protocol

Keywords: critical care muscle loss rectus femoris cross sectional area muscle ultrasound
effectiveness of basic body awareness therapy (bbat) in patients suffering from fibromyalgia

Conditions: Fibromyalgia

Summary: a randomized trial of basic body awareness therapy (bbat) is applied in fibromyalgia patients as compared with a control intervention consisting of treatment as an usual. sessions of bbat lasted 90 minutes each and took place twice a week for 5 weeks. the primary end point is a change in the visual analog scale score and body awareness rating scale and the secondary end points include hospital anxiety depression, state trait anxiety inventory, beck depression inventory and short form 36. all assessments will be repeated at post treatment, 12 weeks and 24 weeks

this work is a clinical trial of randomised and controlled groups. the hypothesis of study is that basic body awareness therapy applied in patients with fibromyalgia improves, more than usual treatment, the pain, normalization of postural pattern and movement, improve in psychologic state and improve of quality life. the study population will be selected followed the inclusion criteria of fibromyalgia, and will be selected in area of primary health center, the patients will be divided in 2 groups, control group and treatment group. the groups will be examined at the begin, at 1 month of the begin of treatment, in 3 months, 6 months and one year to evaluated the outcomes in long time. the dependence measurements will be visual analog scale, basic body awareness rating scale (bars), sf-36, stai a/r, bdi-ii. the independence measurements will be demographic items: sex, age, country, level of studies, social status,..

Eligibility criteria:
inclusion criteria: * patients diagnosed of fibromyalgia according the american college of rheumatology with 6 months at least * the patients have to stay in different position as lying, sitting and standing exclusion criteria: * pregnancy * suffering from another diseases that increase the pain or another specific diagnosis as rheumatic, heart disease and infectious disease

Keywords: body awareness therapy physical therapy movement therapy
anesthetic approaches for dacryocystorhinostomy surgery: the effect of adding local anesthesia to general inhalational anesthesia

Conditions: Effects of; Anesthesia, Local,Pain,in DISE

Summary: to study the effect of combination of of general anesthesia and local anesthesia in anesthesia for external dacryocystorhinostomy and assess quality of the procedure

* calculate the total requirement for anaesthetic agents to maintain satisfactory operating conditions * calculate total anesthetic time * assess intraoperative changes in hemodynamics * assess intraoperative blood loss * evaluate surgeon and patient satisfaction * recognize whether this was related with changes in postoperative analgesia . * also occurrence of postoperative nausea was recorded and compared with general anaesthesia combined with intravenous opioid for (ext-dcr) surgery.

Eligibility criteria:
inclusion criteria:• age from 20 to 50 years old. * american society of anesthesiologists (asa) physical status i or ii. * elective unilateral dacryocystorhinostomy with paranasal skin incision. exclusion criteria: * endoscopic dacryocystorhinostomy. * allergy to amide local anesthetics or opioids. * drug abuse. * pregnancy.
a retrospective cohort study outcome of treatment in asymptomatic stage 4 colorectal cancer

Conditions: Stage IV Colon Cancer

Summary: in asymptomatic stage 4 colorectal cancer, the treatment varies between many hospitals and countries. some studies found that primary tumor resection had better survival rates and a lower risk of mortality. but many studies found significant benefits in survival in sub groups of the population such as age less than 70 years, who performance status \<2, no extra-hepatic metastasis, liver tumor burden \<50%. however some studies showed no survival benefits in primary tumor resection. so this study will focus on survival, adverse events, complications in primary tumor resection and no primary tumor resection in asymptomatic stage 4 colorectal cancer.

the retrospective study of patients in asymptomatic stage 4 colorectal cancer received treatment at ramathibodi hospital and excluded symptomatic primary tumors such as obstruction, perforation that required surgery, carcinomatosis peritoneii, and patients with secondary cancer diagnosis in the past 5 years.

Eligibility criteria:
inclusion criteria: * asymptomatic stage iv colorectal cancer * pathological prove adenocarcinoma * age \>18 years * no primary tumor related symptom * ecog performance status \<2 exclusion criteria: * symptomatic primary tumor such as obstruction , perforation that required surgery * carcinomatosis peritoneii * patients with secondary cancer diagnosis in 5 years
screening for early lung cancer in shanghai, china

Conditions: Lung Cancer

Summary: imaging procedures including chest x-ray and low-dose computed tomography may be effective in lung cancer early detection. yet it is unknown whether low-dose computed tomography combined with computer aided detection （cad) is more effective than ldct in screening of early lung cancer.

the randomized clinical trial is to investigate and compare the effectiveness of cad-guided low-dose computed tomography and low-dose computed tomography in lung cancer screening for community individuals in shanghai, china. thus, an imaging protocol which can detect early lung cancer in asymptomatic high risk patients will be proposed.

Eligibility criteria:
inclusion criteria: * age of 55 to 74 years; smoking history of at least 30 pack-years; and if former smoker, have quit within 15 years * age 50 or older ,20 or more pack-year history of smoking, and one additional risk factor (occupational exposure, residential radon exposure, cancer history, family history of lung cancer, history of lung disease) * age 35 and one additional risk factor * ability to accept ldct examination and sign informed consent form exclusion criteria: * individuals with any symptoms suggestive of lung cancer （e.g., vigorous coughing, chest pain, weight loss, blood-stained sputum） * individuals with acute pulmonary abnormalities or those in poor health conditions or those have metallic implants or devices in the chest or back will be excluded due to the potential impact on the results as well as difficulty of acquiring the images. * pregnant women
validity of peek psi containing autogenous bone graft for maxillary reconstruction following lesion enucleation

Conditions: Maxillary Cyst

Summary: surgical ablation of large maxillary cysts usually results in considerable hard and soft tissue deficits that ultimately affect the final esthetic and functional outcomes. reconstruction of such defects; whether primarily or secondarily; offers much better long-term outcomes. however, primary bony reconstruction becomes potentially complicated in many cases of such large cysts encroaching or involving the maxillary sinus where a communication with the maxillary sinus lining may be unavoidable. reconstruction of such defects can be accomplished using either vascularized or; more commonly; non-vascularized autogenous bone grafts. different bone substitutes remain to be another viable option. the simultaneous use of titanium meshes provides physical three-dimensional support for the bone graft contained within as well as the overlying soft tissues. however, the drawbacks of titanium meshes in such defects remain to be mainly the difficulty in adequately shaping the mesh and the lack of proper isolation of the mesh contents from the maxillary sinus cavity.


Eligibility criteria:
inclusion criteria: 1. age of patients from 15 to 60 years old. 2. patients with unilateral maxillary lesion encroaching maxillary sinus. 3. dentulous or edentulous patients. 4. patients should be free from any systemic disease that may affect normal healing of bone and predictable outcome. exclusion criteria: 1. patients with systemic diseases as history of radiation therapy or chemotherapy, hematological disorders, neuromotor disorders and autoimmune diseases (may affect normal healing). 2. patients with bilateral maxillary lesions. 3. children under 15 years old.
quality of life and autonomy in health of overweight or obese people receiving reinforced support

Conditions: Obesity

Summary: this mixed-methods prospective cohort study aims to evaluate a recently implemented reinforced support program named "x-ailes program". the x-ailes program is a face-to-face or telephone-based support program by health-system navigators/case-managers, funded by the french ministry of health (program for empowerment of care users). x-ales is developed by an patients and public association to support overweight or obese care users facing difficulty to access to care or resources regarding the management of their health situation. the subjects of the present study are the overweight or obese care-users followed-up by the x-ailes program. the aim of the study eval-x-ailes is to assess the effect of the support program x-ailes on quality of life, autonomy and literacy of overweight or obese care users at 12 months.


Eligibility criteria:
inclusion criteria: * people aged 18 or more, male or female * body mass index equal or over 25 * resident living in one of the 2 territories covered by the x-ailes program (lyon metropolitan area or puy-de-dôme county) * starting included in the x-ailes program support (1st phone contact to initiate follow-up) * not objecting to participating in the evaluation of the x-ailes program exclusion criteria: * refusal to participate

Keywords: obesity overweight empowerment autonomy